A MULTI-TARGET PLATFORM

Avineuro has been developing novel molecules with improved pharmacokinetics, efficacy, and safety properties compared to late-stage development compounds.
Avineuro’s drug candidates AVN-101 and AVN-397 are now in clinical development for anxiety and Alzheimer’s disease. Both molecules possess excellent DMPK/tox and behavioral profiles.

A SELECTIVE 5-HT6 RECEPTOR ANTAGONIST PLATFORM

The best in class AVN-211 in Psychiatric disorders and AVN-322 in Alzheimer disease are in Phase II and I Clinical trials respectively. Several more backup compounds are in preclinical development.